Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Link Between Non-Alcoholic Fatty Liver Disease and Certain Cancers

      December 27, 2017
      By Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
      Article

      Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cancer, according to a recent report about a 7.5-year Korean study.

      People with non-alcoholic fatty liver disease (NAFLD) are at a greater risk of developing cancer that those who don't have it, according to a study published in the Journal of Hepatology.

      Researchers in Korea investigated Korean cancer incidence rates among people with NAFLD since there has been insufficient data on whether there is an association between the two. Ultrasonography was used to diagnose NAFLD in the absence of known liver disease, including alcohol-related and viral hepatitis.

      Of 25,947 people studied, 8721 (33.6%) had NAFLD. During the follow-up that averaged 7.5 years, the cancer incidence rate of the NAFLD group was significantly higher than that of the non-NAFLD group. NAFLD was associated with the development of 3 cancers: hepatocellular carcinoma, colorectal cancer in men, and breast cancer in women. Although the study followed Korean patients, the large number of people studied suggests that NAFLD may be prevalent in other countries, too.

      Since NAFLD is affected by the amount of fat in the liver, people who are overweight or obese, have diabetes, or high blood pressure often are at risk. The number of these people worldwide is growing; consequently, the incidence of NAFLD may rise. The American Liver Foundation cites a 25% incidence of NAFLD among Americans, so clinicians in the United States need to be aware of the association between NAFLD and cancer, and screen people at high risk.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      a man wearing a suit and tie in front of a green screen with the ONN logo
      Karyn Goodman
      Expert in oncology
      Expert in oncology
      Experts in oncology
      Expert in oncology
      Expert in oncology
      Expert in oncology
      Expert in oncology
      Related Content

      Graphic of a person's gastrointestinal tract.

      Retifanlimab Lengthens Survival for Patients With Anal Cancer

      Sabrina Serani
      July 24th 2025
      Article

      The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Graphic of a person's esophagus and stomach

      Zanidatamab/Chemo Yields Durable Response in HER2+ Gastroesophageal Cancer

      Russ Conroy
      July 10th 2025
      Article

      Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      Anatomical rendering of the human body with the colon highlighted

      Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer

      Tony Berberabe, MPH
      May 22nd 2025
      Article

      Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

      Related Content

      Graphic of a person's gastrointestinal tract.

      Retifanlimab Lengthens Survival for Patients With Anal Cancer

      Sabrina Serani
      July 24th 2025
      Article

      The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Graphic of a person's esophagus and stomach

      Zanidatamab/Chemo Yields Durable Response in HER2+ Gastroesophageal Cancer

      Russ Conroy
      July 10th 2025
      Article

      Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      Anatomical rendering of the human body with the colon highlighted

      Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer

      Tony Berberabe, MPH
      May 22nd 2025
      Article

      Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

      Latest Conference Coverage

      Understanding How On-Target and Off-Target ADC Toxicities Work

      Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers

      Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.